Pozen: ROTH Conference (Pozen) - Mar 20, 2013 - "Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 months"; "PA32540: Positive Top-Line Results from Two Pivotal Phase 3 Studies"; "Primary endpoint met: Cumulative observed incidence of gastric ulcers over six months"; "Key secondary endpoints met: Cumulative incidence of gastric and duodenal ulcers, Discontinuation due to pre-specified UGI adverse events, Heartburn resolution"; "Completed long-term safety study: (N=379) with no unexpected findings, and AEs consistent with the population and known profiles of ASA and omeprazole"
P3 data: top line • Acute Coronary Syndrome
|